Literature DB >> 9009227

Inhibition of epithelial Na+ currents by intracellular domains of the cystic fibrosis transmembrane conductance regulator.

K Kunzelmann1, G L Kiser, R Schreiber, J R Riordan.   

Abstract

Cystic fibrosis is characterized by an impaired cyclic adenosine 3,5-monophosphate (cAMP) activated Cl- conductance in parallel with an enhanced amiloride sensitive Na+ conductance (ENaC) of the respiratory epithelium. Very recently, acute downregulation of ENaC by the cystic fibrosis transmembrane conductance regulator (CFTR) was demonstrated in several studies. The mechanism, however, by which CFTR exerts its inhibitory effect on ENaC remains obscure. We demonstrate that cytosolic domains of human CFTR are sufficient to induce inhibition of rat epithelial Na+ currents (rENaC) when coexpressed in Xenopus oocytes and stimulated with 3-isobutyl-1-methylxanthine (IBMX). Moreover, mutations of CFTR, which occur in cystic fibrosis, abolish CFTR-dependent downregulation of rENaC. Yeast two hybrid analysis of CFTR domains and rENaC subunits suggest direct interaction between the proteins. Enhanced Na+ transport as found in the airways of cystic fibrosis patients is probably due to a lack of CFTR dependent downregulation of ENaC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9009227     DOI: 10.1016/s0014-5793(96)01414-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  31 in total

1.  The first-nucleotide binding domain of the cystic-fibrosis transmembrane conductance regulator is important for inhibition of the epithelial Na+ channel.

Authors:  R Schreiber; A Hopf; M Mall; R Greger; K Kunzelmann
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 2.  Proteases, cystic fibrosis and the epithelial sodium channel (ENaC).

Authors:  P H Thibodeau; M B Butterworth
Journal:  Cell Tissue Res       Date:  2012-05-22       Impact factor: 5.249

Review 3.  Airway hydration and COPD.

Authors:  Arunava Ghosh; R C Boucher; Robert Tarran
Journal:  Cell Mol Life Sci       Date:  2015-06-12       Impact factor: 9.261

4.  Defective regulatory volume decrease in human cystic fibrosis tracheal cells because of altered regulation of intermediate conductance Ca2+-dependent potassium channels.

Authors:  E Vázquez; M Nobles; M A Valverde
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

5.  Chloride channel and chloride conductance regulator domains of CFTR, the cystic fibrosis transmembrane conductance regulator.

Authors:  E M Schwiebert; M M Morales; S Devidas; M E Egan; W B Guggino
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

6.  Gating of amiloride-sensitive Na(+) channels: subunit-subunit interactions and inhibition by the cystic fibrosis transmembrane conductance regulator.

Authors:  B K Berdiev; V G Shlyonsky; K H Karlson; B A Stanton; I I Ismailov
Journal:  Biophys J       Date:  2000-04       Impact factor: 4.033

Review 7.  Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.

Authors:  Ronald C Rubenstein
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 8.  Pouring salt on a wound: Pseudomonas aeruginosa virulence factors alter Na+ and Cl- flux in the lung.

Authors:  Alicia E Ballok; George A O'Toole
Journal:  J Bacteriol       Date:  2013-07-08       Impact factor: 3.490

9.  The cystic fibrosis transmembrane conductance regulator (CFTR) inhibits ENaC through an increase in the intracellular Cl- concentration.

Authors:  J König; R Schreiber; T Voelcker; M Mall; K Kunzelmann
Journal:  EMBO Rep       Date:  2001-10-17       Impact factor: 8.807

10.  Two salt bridges differentially contribute to the maintenance of cystic fibrosis transmembrane conductance regulator (CFTR) channel function.

Authors:  Guiying Cui; Cody S Freeman; Taylor Knotts; Chengyu Z Prince; Christopher Kuang; Nael A McCarty
Journal:  J Biol Chem       Date:  2013-05-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.